Role of the endogenous cannabinoid system in nicotine addiction: novel insights
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Several lines of evidence have shown that the endogenous cannabinoids are implicated in several neuropsychiatric diseases. Notably, preclinical and human clinical studies have shown a pivotal role of the cannabinoid system in nicotine addiction. The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. Rimonabant has been shown to improve the ability of smokers to quit smoking in randomized clinical trials. However, rimonabant was removed from the market due to increased risk of psychiatric side-effects observed in humans. Recently, other components of the endogenous cannabinoid system have been explored. Here, we present the recent advances on the understanding of the role of the different components of the cannabinoid system on nicotine's effects. Those recent findings suggest possible alternative ways of modulating the cannabinoid system that could have implication for nicotine dependence treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2023) · doi:10.1126/science · Cited by 6,063
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 2×
“CB1 receptors are among the most abundant G-protein-coupled receptors in the central nervous system (CNS) (22).”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 2×
“These findings suggest that anandamide and 2-AG might have different actions according to the different physiological or pathophysiological conditions under which they are synthesized (17).”
BackgroundEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“The respective inhibition of GABA or glutamate release by endocannabinoids mediate depolarization-induced suppression of “inhibition”(DSI) (39, 40) or the depolarization-induced suppression of “excitation” (DSE) (41), respectively.”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“carbamic acid 3-carbamoyl-3-yl ester (URB597) produce elevation of anandamide levels by blocking anandamide reuptake or by inhibiting FAAH, respectively (105, 106).”
BackgroundSchultz, W., Apicella, P., & Ljungberg, T. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-03-00900.1993 · Cited by 1,291
A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177 · cited 1×
“The remaining 2AG seems to be hydrolyzed by ABHD6 and ABHD12 enzymes (36), although the information on this regard is limited.”
BackgroundThe endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · cited 1×
“CB1 receptors are believed to be the main mediators of the psychoactive properties of delta-9-tetrahydrocannabinol (THC), which is the main psychoactive component of cannabis (21).”
BackgroundEffects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Nicotine activates and desensitizes midbrain dopamine neurons
Pidoplichko, V. I., DeBiasi, M., Williams, J. T., & Dani, J. A. (1997) · Nature · doi:10.1038/37120 · Cited by 769
(2014) · doi:10.1523/jneurosci · Cited by 715
Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09506.2001 · Cited by 668 · cited 1×
“The ability of endocannabinoids to act as retrograde neurotransmitters (44) allows them to attenuate the activity of external afferents (pre-synaptic neurons) (42) and allows dopamine neurons (post-synaptic neurons) to regulate their own function (43).”
BackgroundFegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397
Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 4×
“The critical role of endocannabinoids mediating the ability of drugs of abuse, including nicotine, to stimulate reward pathway is shown by multiple pharmacological studies (14, 79, 80).”
BackgroundInfluentialPhasic Dopamine Release Evoked by Abused Substances Requires Cannabinoid Receptor Activation
Cheer, J. F., Wassum, K. M., Sombers, L. A., Heien, M. L. A. V., Ariansen, J. L., Aragona, B. J., Phillips, P. E. M., & Wightman, R. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-06.2007 · Cited by 374 · cited 1×
“The critical role of endocannabinoids mediating the ability of drugs of abuse, including nicotine, to stimulate reward pathway is shown by multiple pharmacological studies (14, 79, 80).”
BackgroundNicotinic receptors in the brain. Links between molecular biology and behavior
Picciotto, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00146-3 · Cited by 354
Egertová, M., Cravatt, B. F., & Elphick, M. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00145-3 · Cited by 347
Anandamide Amidohydrolase Activity in Rat Brain Microsomes
Desarnaud, F., Cadas, H., & Piomelli, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6030 · Cited by 336
Zhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334 · cited 1×
“Another recent study by Zhang and colleagues, reported that activation of CB2 receptors in the VTA can attenuate cocaine self-administration in WT and CB1 knockout but not in CB2 knockout mice (101).”
BackgroundValenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L., Mark, L., Pearson, M. S., Miller, W., Shan, S., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.008 · Cited by 288 · cited 1×
“In fact, the effects of CB1 and CB2 receptor activation (at high doses) can produce similar effects such as antinociception and catalepsy (97, 98).”
BackgroundBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Cohen, C., Perrault, G., Griebel, G., & Soubrié, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300541 · Cited by 251
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230
Mátyás, F., Urbán, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., & Katona, I. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.028 · Cited by 187 · cited 7×
“Another recent study by Zhang and colleagues, reported that activation of CB2 receptors in the VTA can attenuate cocaine self-administration in WT and CB1 knockout but not in CB2 knockout mice (101).”
BackgroundInfluentialRahn, E. J., Makriyannis, A., & Hohmann, A. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707333 · Cited by 146 · cited 1×
“In fact, the effects of CB1 and CB2 receptor activation (at high doses) can produce similar effects such as antinociception and catalepsy (97, 98).”
BackgroundBerrendero, F., Robledo, P., Trigo, J. M., Martín-García, E., & Maldonado, R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.006 · Cited by 140
Self-citationMateos, B., Borcel, E., Loriga, R., Luesu, W., Bini, V, Llorente, R., Castelli, M., & Viveros, M.-P. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110370503 · Cited by 108 · cited 1×
“However, more recent findings have reported modification in the number of nicotine receptors following chronic exposure to cannabinoids (137).”
BackgroundKenny, P. J., File, S. E., & Neal, M. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752409.x · Cited by 100
Melis, M., Carta, S., Fattore, L., Tolu, S., Yasar, S., Goldberg, S. R., Fratta, W., Maskos, U., & Pistis, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.016 · Cited by 89 · cited 2×
“The similar effects of URB597 and rimonabant described above could be explained by the involvement of non-cannabinoid peroxisome proliferatoractivated nuclear receptor (PPAR-α) systems (110, 111).”
Cited by
The neurobiology of social play and its rewarding value in rats
Vanderschuren, L. J. M. J., Achterberg, E. J. M., & Trezza, V. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.025 · Cited by 329
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
Enhancement of meditation analgesia by opioid antagonist in experienced meditators
May, L. M., Kosek, P., Zeidan, F., & Berkman, E. T. (2018) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000580 · Cited by 24
Metadata
- Authors
- Gamaleddin, I. H.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2015
- Volume
- 6
- Pages
- 41-41
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2048743691
- Cited by
- 58
- References
- 34
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.